{"id":13595,"date":"2024-01-16T10:06:15","date_gmt":"2024-01-16T09:06:15","guid":{"rendered":"https:\/\/pharmavalue.it\/?p=13595"},"modified":"2024-01-16T10:45:59","modified_gmt":"2024-01-16T09:45:59","slug":"interministerial-decree-published-for-new-aifa-regulation","status":"publish","type":"post","link":"https:\/\/pharmavalue.it\/en\/interministerial-decree-published-for-new-aifa-regulation\/","title":{"rendered":"Interministerial Decree for new AIFA regulation published"},"content":{"rendered":"<p style=\"font-weight: 400;\"><strong>Published<\/strong> yesterday, 15 January 2024, <strong>In the OJ the Ministerial Decree for the reform of AIFA, which will enter into force on 30 January 2024.<\/strong><\/p>\n<p style=\"font-weight: 400;\">The Ministerial Decree concerning the reform of AIFA and the establishment of the Scientific Economic Commission (CSE) was signed on 8 January by the Minister of Health (Orazio Schillaci), the Minister of Public Administration (Paolo Zangrillo) and the Minister of Economy and Finance (Giancarlo Giorgetti).<\/p>\n<p style=\"font-weight: 400;\"><strong>The final version has undergone changes compared to the one presented at the State-Regions Conference in October 2023<\/strong>following requests from the CSR and some comments from the Council of State.<\/p>\n<p style=\"font-weight: 400;\">I <strong>main changes<\/strong> made since the last version <strong>are<\/strong> the following:<\/p>\n<ul>\n<li><strong>ART. 5<\/strong>\u00a0It is envisaged that the President will be appointed by decree of the Minister of Health\u00a0<strong>in agreement<\/strong> with the Permanent Conference for Relations between the State, the Regions and the Autonomous Provinces of Trento and Bolzano\u00a0<span class=\"cqiun4t2 khvhiq1o r5qsrrlp i5tg98hk iqx13udk przvwfww qiohso4h gfz4du6o r7fjleex nz2484kf svot0ezm dcnh1tix sxl192xd t3g6t33p\"><span class=\"\">\u27a1\ufe0f <\/span><\/span><span style=\"color: #ff0000;\"><strong>In the previous version, 'after hearing the CSR' was indicated.<\/strong><\/span><\/li>\n<\/ul>\n<ul>\n<li><strong>ART. 6<\/strong>\u00a0Peremptory character of the<strong>exclusivity of assignment<\/strong>\u00a0of the President with respect to other professional activities\u00a0 <span class=\"cqiun4t2 khvhiq1o r5qsrrlp i5tg98hk iqx13udk przvwfww qiohso4h gfz4du6o r7fjleex nz2484kf svot0ezm dcnh1tix sxl192xd t3g6t33p\"><span class=\"\">\u27a1\ufe0f <span style=\"color: #ff0000;\"><strong>n<\/strong><\/span><\/span><\/span><span style=\"color: #ff0000;\"><strong>n the previous version it was stated: 'Unless the decree of appointment provides otherwise, the office of President is exclusive...'.<\/strong><\/span><\/li>\n<li><strong>ART. 9<\/strong>\u00a0It is expected that the appointment of\u00a0<strong>Administrative Director<\/strong>\u00a0is conferred by decree of the Minister of Health\u00a0<u>After consulting the Permanent Conference for Relations between the State, the Regions and the Autonomous Provinces of Trento and Bolzano<\/u> <span class=\"cqiun4t2 khvhiq1o r5qsrrlp i5tg98hk iqx13udk przvwfww qiohso4h gfz4du6o r7fjleex nz2484kf svot0ezm dcnh1tix sxl192xd t3g6t33p\"><span class=\"\">\u27a1\ufe0f <span style=\"color: #ff0000;\"><strong>n<\/strong><\/span><\/span><\/span><span style=\"color: #ff0000;\"><strong>n the previous version, the CSR was not indicated.<\/strong><\/span><\/li>\n<li><strong>ART. 10<\/strong>\u00a0provides that the appointment of\u00a0<strong>Technical Scientific Director<\/strong>\u00a0is conferred by decree of the Minister of Health\u00a0<u>After consulting the Permanent Conference for Relations between the State, the Regions and the Autonomous Provinces of Trento and Bolzano<\/u> <span class=\"cqiun4t2 khvhiq1o r5qsrrlp i5tg98hk iqx13udk przvwfww qiohso4h gfz4du6o r7fjleex nz2484kf svot0ezm dcnh1tix sxl192xd t3g6t33p\"><span class=\"\">\u27a1\ufe0f <\/span><\/span>\u00a0<span style=\"color: #ff0000;\"><strong>In the previous version, the CSR was not indicated.<\/strong><\/span><\/li>\n<li><strong>ART. 14<\/strong>\u00a0It is envisaged that the general-level management structures are divided into 6 non-general-level management areas and into\u00a0<strong>43\u00a0<\/strong><strong>Executive Offices<\/strong>\u00a0of non-general management level <span class=\"cqiun4t2 khvhiq1o r5qsrrlp i5tg98hk iqx13udk przvwfww qiohso4h gfz4du6o r7fjleex nz2484kf svot0ezm dcnh1tix sxl192xd t3g6t33p\"><span class=\"\">\u27a1\ufe0f <\/span><\/span>\u00a0<span style=\"color: #ff0000;\"><strong>38 offices were indicated in the previous version.<\/strong><\/span><\/li>\n<li><strong>ART. 15<\/strong>\u00a0It is envisaged that the Scientific and Economic Medicine Commission will be appointed by decree of the Minister of Health and will be composed of 10 members, of whom\u00a0<strong>three members appointed by the State-Regions Conference<\/strong>\u00a0<span class=\"cqiun4t2 khvhiq1o r5qsrrlp i5tg98hk iqx13udk przvwfww qiohso4h gfz4du6o r7fjleex nz2484kf svot0ezm dcnh1tix sxl192xd t3g6t33p\"><span class=\"\">\u27a1\ufe0f <span style=\"color: #ff0000;\"><strong>n<\/strong><\/span><\/span><\/span><span style=\"color: #ff0000;\"><strong>n the previous version, the CSR appointed only 1 non-executive member.<\/strong><\/span><\/li>\n<\/ul>\n<p>In the pdf document a summary of the decree.<\/p>\n<div class=\"_df_book df-lite\" id=\"df_13617\"  _slug=\"regolamento-recante-modifiche-al-regolamento-sullorganizzazione-e-sul-funzionamento-dellagenzia-italiana-del-farmaco-aifa\" data-title=\"regolamento-recante-modifiche-al-regolamento-sullorganizzazione-e-sul-funzionamento-dellagenzia-italiana-del-farmaco-aifa\" wpoptions=\"true\" thumbtype=\"\" ><\/div><script class=\"df-shortcode-script\" nowprocket type=\"application\/javascript\">window.option_df_13617 = {\"outline\":[],\"backgroundColor\":\"eeeeee\",\"duration\":\"0\",\"autoEnableOutline\":\"false\",\"autoEnableThumbnail\":\"false\",\"overwritePDFOutline\":\"false\",\"enableDownload\":\"true\",\"direction\":\"1\",\"pageSize\":\"0\",\"pageMode\":\"1\",\"soundEnable\":\"false\",\"autoPlay\":\"false\",\"source\":\"https:\\\/\\\/pharmavalue.it\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Decreto-interministeriale-per-nuovo-regolamento-AIFA.pdf\",\"wpOptions\":\"true\"}; if(window.DFLIP && window.DFLIP.parseBooks){window.DFLIP.parseBooks();}<\/script>","protected":false},"excerpt":{"rendered":"<p>Pubblicato ieri, 15 gennaio 2024, in GU il DM per la riforma di AIFA, che entrer\u00e0 in vigore il 30 gennaio 2024. Il Decreto Ministeriale riguardante la riforma dell\u2019AIFA e la costituzione della Commissione Scientifica economica (CSE) \u00e8 stato firmato l\u20198 gennaio dal Ministro della Salute (Orazio Schillaci), il Ministro della Pubblica Amministrazione (Paolo Zangrillo) [&hellip;]<\/p>\n","protected":false},"author":314,"featured_media":12813,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_seopress_titles_title":"Pubblicato il Decreto interministeriale per nuovo regolamento AIFA","_seopress_titles_desc":"Pubblicato ieri, 15 gennaio 2024, in GU il DM per la riforma di AIFA, che entrer\u00e0 in vigore il 30 gennaio 2024.\r\n\r\nIl Decreto Ministeriale riguardante la riforma dell\u2019AIFA e la costituzione della Commissione Scientifica economica (CSE) \u00e8 stato firmato l\u20198 gennaio dal Ministro della Salute, il Ministro della Pubblica Amministrazione e il Ministro dell\u2019Economia e delle Finanze.","_seopress_robots_index":"","footnotes":""},"categories":[38],"tags":[],"class_list":["post-13595","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analisi-di-scenario"],"_links":{"self":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/13595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/users\/314"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/comments?post=13595"}],"version-history":[{"count":0,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/posts\/13595\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media\/12813"}],"wp:attachment":[{"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/media?parent=13595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/categories?post=13595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmavalue.it\/en\/wp-json\/wp\/v2\/tags?post=13595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}